Atraverse Medical is known for its Hotwire transseptal access system, a radiofrequency guidewire designed for left-heart access. The device enables zero-exchange access while also functioning as a support rail for catheter-based therapies. Developed by Steven Mickelsen alongside co-founder Eric Sauter, the system reflects continued innovation in electrophysiology tools. Mickelsen previously founded Farapulse, which was acquired by Boston Scientific in 2021. The system has already been deployed in more than 3,000 clinical procedures, underscoring its early adoption in interventional cardiology settings.

Regulatory milestones have supported the platform’s progress. The device initially received clearance from the U.S. Food and Drug Administration in May 2024, followed by an additional clearance in December 2025 for the Hotwire RF generator integrated with the guidewire. This generator is designed to mitigate the risk of uncontrolled energy delivery once access to the left atrium is achieved, while also allowing activation within the sterile field to improve procedural control. Earlier this year, Atraverse reported positive clinical findings associated with the system.

According to Johnson & Johnson, the addition of Atraverse Medical will enhance its cardiac ablation portfolio, which includes platforms such as Varipulse and the Carto 3 mapping system. The Hotwire system’s features — including impedance sensing with automatic energy shutoff, compatibility with multiple sheaths, and visibility under intracardiac echocardiography — are expected to complement existing technologies. The Atraverse Medical acquisition reflects the company’s continued focus on advancing minimally invasive solutions in electrophysiology.

The initiative, jointly introduced by the Centers for Medicare and Medicaid Services and the U.S. Food and Drug Administration, is formally known as the Regulatory Alignment for Predictable and Immediate Device, or Rapid. It is designed for technologies that already qualify for expedited regulatory review due to their potential to address unmet medical needs. By synchronising FDA evaluation timelines with CMS coverage considerations, the program integrates reimbursement planning earlier in the product lifecycle, reducing delays that typically arise after regulatory clearance.

“The American people deserve timely access to meaningful treatments without red tape or high costs,” FDA Commissioner Marty Makary said in a statement.

Devices expected to fall within the scope of the program include artificial heart valves, cardiac rhythm management technologies, and nerve-stimulation implants used in disease treatment. According to CMS chief policy and regulatory officer John Brooks, approximately 40 devices currently meet eligibility criteria, with an additional 20 potentially qualifying. These products are often developed by leading medical technology companies such as Medtronic Plc, Boston Scientific Corp., and Abbott Laboratories, reflecting the high level of innovation targeted by the pathway.

• The program aligns FDA approval timelines with CMS reimbursement decisions
• Coverage timelines may shrink from over a year to as little as two months
• Around 40 devices are immediately eligible, with 20 more under consideration
• Focus areas include cardiac devices, implants, and nerve stimulation technologies

For device manufacturers, delays in securing reimbursement have long represented a critical commercial and operational challenge, frequently extending development cycles and limiting market entry. The fragmented nature of coverage where access varies by region has further complicated adoption. Central to this issue is the National Coverage Determination process, which defines whether Medicare and Medicaid will reimburse specific technologies. Although private insurers are not formally bound by these decisions, they often align with federal determinations, amplifying their industry-wide impact. The new framework aims to reduce these inefficiencies and provide a more predictable pathway for each Breakthrough Medical Device entering the healthcare system.

The agency’s letter provides detailed guidance on manufacturer responsibilities, while reinforcing the need for proactive engagement with regulators to ensure continued product safety and effectiveness.

Regulatory Direction and Manufacturer Responsibilities

The FDA’s communication establishes a clear compliance framework for healthcare manufacturers. It emphasizes that organisations must take full responsibility for identifying potential nitrosamine impurities originating from both pharmaceutical ingredients and manufacturing processes.

Manufacturers are expected to:

• Conduct comprehensive risk assessments as part of biocompatibility evaluations
• Develop and deploy analytical testing methods to detect and control impurities
• Assess patient exposure levels relative to FDA-defined acceptable intake limits
• Investigate all possible contamination pathways, including manufacturing, sterilisation, and storage

The agency also advises manufacturers to consult existing FDA guidance, including standards related to nitrosamine control and biological evaluation frameworks such as ISO 10993-1.

Identified Risks in Drug-Device Combination Products

CDRH has identified the presence of 1-methyl-4-nitrosopiperazine (MNP) a nitrosamine impurity in certain combination products containing the antibiotic rifampin. Nitrosamines are classified as probable carcinogens, and prolonged exposure above acceptable thresholds may elevate cancer risk.

While no specific products or manufacturers have been named, the agency highlighted multiple categories of devices where rifampin is commonly used:

• Antimicrobial-coated catheters, including central venous and ventricular variants
• Cardiac implant accessories such as antibacterial envelopes used with implantable cardioverter defibrillators (ICDs)
• Neurostimulation and neuromodulation implants
• Prosthetic devices incorporating antibiotic surface treatments

Ongoing Investigation and Regulatory Engagement

The FDA confirmed that investigations into the root causes and scope of nitrosamine formation are ongoing. At present, the agency has not identified any adverse events linked to these impurities in CDRH-regulated products. However, the absence of reported cases has not reduced the urgency of regulatory action.

CDRH is working closely with manufacturers to:

• Determine the mechanisms behind nitrosamine formation
• Evaluate the applicability of interim or alternative exposure limits
• Standardise risk assessment methodologies across product categories

Manufacturers identifying potential risks are advised to engage with the FDA via the Q-Submission process, enabling early regulatory feedback and alignment on mitigation strategies.

Operational and Compliance Implications for Healthcare Management

From a healthcare management perspective, the FDA’s directive introduces heightened compliance expectations across product lifecycle management. Organisations must integrate impurity risk assessment into broader quality systems, particularly in areas involving supply chain oversight, raw material sourcing, and manufacturing validation.

As observed by HHM Global, this development signals a shift toward more integrated regulatory oversight of combination products, where pharmaceutical and device standards increasingly converge. HHM Global notes that manufacturers will need to strengthen cross-functional coordination between regulatory affairs, quality assurance, and production teams to manage emerging risks effectively.

The emphasis on nitrosamine impurity risk also reinforces the importance of data-driven monitoring frameworks, ensuring that potential contamination sources are identified early and mitigated before reaching clinical use.

Strategic Industry Relevance

The FDA’s action reflects a broader regulatory trend toward tighter control of impurities in complex healthcare products. For manufacturers, this translates into increased investment in analytical capabilities, enhanced supplier collaboration, and more rigorous validation protocols.

In practical terms, HHM Global highlights that this move could reshape compliance strategies for combination product manufacturers, particularly those relying on antibiotic-impregnated devices. The regulatory focus on impurity pathways from raw materials to finished products positions nitrosamine risk management as a critical component of long-term product safety governance.

The newly cleared Rembra platform is designed to help healthcare providers manage rising demand for imaging services while improving operational efficiency and access to high-quality diagnostics. According to Philips, the platform extends the application of computed tomography across radiology and radiation therapy, enabling more integrated workflows and coordinated patient management. The systems aim to address clinical complexity by supporting faster imaging processes and more streamlined decision-making pathways.

Within the platform, Rembra CT features an 85-cm bore and is engineered for high-throughput environments, allowing up to 270 exams per day across emergency, critical care and interventional settings. Meanwhile, Rembra RT and Areta RT bring similar imaging capabilities into radiation therapy, supporting treatment planning with high-fidelity imaging, an extended field of view and next-generation 4DCT functionality. Collectively, the Rembra platform establishes a unified CT ecosystem designed to operate across the full care continuum.

Dan Xu, business leader of CT at Philips, said:
“As healthcare systems manage increasing demand and complexity, imaging plays a critical role in enabling timely and informed clinical decisions. With the Rembra platform, we are redefining what clinicians can expect from CT, combining speed, scalability, and precision to expand access to high-quality imaging while supporting confident diagnosis and highly accurate treatment planning.”

The Waltham, Massachusetts-based ophthalmic device manufacturer previously presented Virtuoso to the European surgical community during the 2025 EURETINA and European Society of Cataract and Refractive Surgeons (ESCRS) congresses. According to the company, the system is engineered to deliver stable intraocular pressure (IOP) management, controlled energy output, and advanced vitreous cutting and aspiration, all within a compact footprint intended to streamline operating room workflows. “Virtuoso represents a significant advance in surgical equipment design, bringing together precision, intuitive ease of use that supports OR efficiency, and world-class versatility for both the front and the back of the eye,” said Jim Hollingshead, president and CEO of BVI. “With CE Mark certification under the European Medical Device Regulation, we are making this leading-edge platform available to surgeons across Europe, designed to elevate surgical control, efficiency, and outcomes, reflecting BVI’s continued commitment to meaningful innovation in eye health.”

The platform is designed for anterior, posterior, and combined procedures, with a focus on multi-specialty centres and ambulatory surgical settings. It integrates proprietary technologies across fluidics, energy delivery, and workflow optimisation, including the Equality system for maintaining consistent target IOP, the inVITe valved entry system supporting intraoperative stability, and EvenFlow technology for controlled IOP during fluid-air exchange. The Resolute ultrasound system is intended to maintain consistent energy delivery regardless of lens hardness, while the Velvet probe enables high-speed dual-pneumatic cutting for vitreoretinal applications. The EasyFit setup system is designed to reduce operating room turnover time, reinforcing efficiency in Eye Surgery environments.

A prospective, single-centre, single-arm pre-market clinical investigation is currently underway at LMU Klinikum in Munich, Germany, led by Prof. Siegfried Priglinger, MD, with the first patient procedure completed in December 2025. Scientific data on system performance, including post-occlusion break surge, energy consistency, aspiration efficiency, and cutter stiffness, has been presented at the 2025 EURETINA, ESCRS, and FloRETINA congresses. The platform was also featured in a live surgical demonstration at the Munich Retina Meeting in early 2026. BVI stated that Virtuoso is designed to integrate with its broader portfolio of consumables and intraocular lenses, supporting its global presence across more than 90 countries.

The new module is engineered to integrate with Johnson & Johnson’s SoundStar Crystal (2D ICE) and NuVision Nav (4D ICE) ultrasound catheters, extending its applicability across a range of clinical scenarios. It is intended to support both the planning phase and real-time execution of procedures targeting various heart rhythm conditions, including AFib, ventricular tachycardia and complex concomitant interventions. By embedding AI into the workflow, the company aims to streamline imaging processes and improve procedural efficiency, further strengthening the role of cardiac mapping as a central tool in electrophysiology practice.

Johnson & Johnson continues to align its mapping innovations with its broader therapy platforms. The Carto system remains a foundational component of the company’s Varipulse pulsed field ablation (PFA) platform, which is used in the treatment of AFib. At HRS 2026, the company is also set to present new real-world data related to Varipulse, following the recent introduction of its next-generation platform in Europe. These developments reflect a coordinated strategy to integrate imaging, mapping and therapeutic capabilities within a single connected ecosystem.

“In my experience, CartoSound Sonata elevates imaging capabilities by streamlining the process of building detailed maps of the heart across multiple chambers using both 2D and 4D ICE technologies, even during the most complex concomitant procedures. This new module continues to demonstrate the power and versatility of the CARTO System and is a clear example of its continued evolution as a key platform in electrophysiology,” said Luigi Di Biase, system director, Electrophysiology, Montefiore Health System.

“For 30 years, the Carto system has led progress in electrophysiology, serving as the foundation of a connected platform that brings together imaging, mapping, and therapy. Looking into the future, we are decisively moving forward with continuous advancements toward new frontiers in cardiac mapping. As we introduce CartoSound Sonata and continue to progress our PFA technologies, we remain committed to innovation that improves how arrhythmias are understood and treated, while evolving and pushing what’s possible in AFib care,” said Michael Bodner, company group chair, Electrophysiology & Neurovascular, MedTech, Johnson & Johnson.

The system has been engineered to optimize the entire imaging workflow, from acquisition to reconstruction. By leveraging AI, it reduces system noise, improves image clarity, and accelerates clinical processes. Designed for seamless integration, the platform delivers PACS-native outputs and embeds directly into existing workflows. Spectral imaging enables the analysis of how tissues absorb varying X-ray energy levels, allowing detector-based systems to generate multiple spectral outputs from a single scan without compromising scan time or performance.

The technology is intended for broad clinical application, including radiology, interventional radiology, and cardiology. It also supports oncology workflows, particularly in treatment preparation and radiation therapy planning. The system combines high-definition conventional imaging with advanced spectral capabilities, while AI-driven reconstruction delivers enhanced image quality with reduced noise. Additionally, the platform is designed to lower radiation dose without affecting diagnostic output and can cut energy consumption by up to 45%.

Powered by third-generation Nano-panel Precise dual-layer detector technology, the system significantly improves processing efficiency. It can reconstruct up to 145 images per second and complete full exams in under 30 seconds, enabling throughput of up to 270 exams daily. This represents a twofold speed increase compared to earlier models. The platform builds on proprietary Spectral Precise Imaging technology, incorporating deep learning to refine imaging outcomes.

Dan Xu, Business Leader of CT at Philips, said:
“With FDA clearance for Verida, we are bringing the next evolution of spectral CT to more markets. By combining always-on spectral imaging with AI-powered reconstruction, Verida enables clinicians to see more, first time right, supporting faster, more informed decisions and expanding the role of CT across clinical pathways.”

The partnership, initially established in 2024, was designed to support the integration of artificial intelligence across imaging workflows. At its core, the initiative combines DeepHealth’s AI-driven breast cancer screening tools with GE HealthCare’s Senographe Pristina mammography platform. Since then, both companies have progressively expanded the scope of their collaboration, including plans to extend their offerings beyond the U.S. market and enhance the capabilities of their integrated solutions.

Recent developments center on DeepHealth’s Breast Suite, a cloud-based platform comprising modular and interoperable applications tailored for breast imaging environments. When integrated with GE HealthCare’s Pristina Via system, the suite is positioned to enable scalable and efficient screening programs. The updated Breast Suite introduces additional tools designed for compatibility with GE HealthCare systems, including ProFound Pro, which combines Cancer Detection capabilities with Automated Density Assessment. These features provide automated lesion localization, consistent density classification, and improved diagnostic support. The Safeguard Review functionality further enhances workflows by identifying complex cases that may require secondary evaluation.

Commenting on the collaboration, Jyoti Gupta, president and CEO, Women’s Health and X-ray at GE HealthCare, said:
“At GE HealthCare, we’re advancing women’s health through precision care built around the unique needs of women and enhanced by the power of AI. By integrating Breast Suite AI with our Pristina Via mammography system, we’re helping clinicians detect breast cancer early with greater confidence. These innovations move us closer towards truly personalized prevention and care for women.”

Dr. Niccolo Stefani, business leader, Population Health & Clinical AI, DeepHealth, added:
“At DeepHealth, we are committed to bringing the next era of AI-powered health informatics to help stage shift disease. Through our expanded collaboration with GE HealthCare, we are bringing the power of our new Breast Suite to providers around the world to enable early cancer detection, deeper clinical insights, and more confident decisions.”

The expanded initiative reflects a continued push toward improving clinical accuracy, workflow efficiency, and global accessibility of AI mammography technologies, reinforcing both companies’ commitment to advancing women’s health through data-driven imaging solutions.

In preparation for the rollout, the European Medicines Agency has scheduled an online information session on 24 April 2026. The session will outline key elements of the Breakthrough Devices framework and address practical considerations for stakeholders intending to participate. This step is expected to help manufacturers better understand procedural requirements and align early with regulatory expectations.

The pilot draws from the recently adopted MDCG 2025-9 guidance issued by the Medical Device Coordination Group. It also aligns with broader regulatory revisions proposed by the European Commission in December 2025, which introduced new provisions under Article 52a of the Medical Devices Regulation and Article 48a of the In Vitro Diagnostic Regulation. These updates aim to formalise a future framework for breakthrough medical technologies within the EU.

Positioned as a strategic move, the programme reinforces efforts to foster an innovation-oriented regulatory landscape across Europe. To secure a breakthrough designation, manufacturers must seek an opinion from the agency’s expert panels, with additional guidance and application templates expected ahead of the launch. The pilot also supports wider objectives tied to public health priorities, ensuring that advanced medical technologies entering the EU market continue to meet stringent quality, safety, and performance benchmarks. The Breakthrough Devices pilot is therefore expected to play a defining role in shaping future regulatory processes while strengthening confidence in high-impact innovations. The Breakthrough Devices pilot further underlines the EU’s commitment to balancing innovation with robust oversight.

The integrated solution brings together real-time MRI capabilities with MR-conditional interventional tools and structured clinical workflows. It builds on a partnership formalised in September 2025, when the two companies aligned their expertise—pairing Siemens Healthineers’ imaging technologies with Cook Medical’s procedural specialisation. The system incorporates devices specifically developed for MRI environments alongside the Magnetom Free.XL platform, creating a unified framework for interventional imaging and treatment delivery.

Within the suite, multiple components are integrated to streamline clinical use and expand procedural capabilities:

• Advanced imaging technology designed for real-time guidance during interventions
• Purpose-built interventional devices tailored for MRI compatibility
• Suite planning support and clinical education resources
• Integration with SIR VIRTEX, a clinical data registry and analytics platform
• Continuous data feedback to enhance procedural learning and outcomes

The companies state that this MRI Suite launch enables physicians to perform procedures that benefit from enhanced soft-tissue visibility while avoiding radiation exposure. Applications include oncology and soft-tissue interventions, with use cases spanning biopsies, ablations, and procedures in pediatric and cardiac care. According to Peter Polverini III, VP of Cook Medical’s iMRI division, “The iMRI Suite is more than a technology; it’s a fundamental shift in how we approach intervention. By bringing together advanced imaging, purpose-built devices, and integrated workflows, we are enabling physicians to see more, treat with greater precision, and ultimately deliver better outcomes without exposing patients or care teams to radiation.”

Pete Yonkman, president of Cook Medical and Cook Group, added: “MRI offers unique advantages for image-guided intervention, particularly for procedures involving soft tissue. Through our collaboration with Siemens Healthineers and leading clinicians, we are working to advance the development of radiation-free interventional approaches.” Andreas Schneck, head of Magnetic Resonance at Siemens Healthineers, said: “At Siemens Healthineers, it is our goal to elevate health globally. Magnetom Free.XL is designed to unlock the full potential of MR in the interventional suite, expanding the imaging toolbox by matching the right modality to the right patient at the right time.”